AZD5363 in Patients (Pts) with Tumors with AKT Mutations: NCI-MATCH Subprotocol EAY131-Y, A Trial of the ECOG-ACRIN Cancer Research Group (EAY131-Y)

SY-1365, a selective CDK7 inhibitor, enhances carboplatin activity in ovarian cancer cell lines and xenografts, and transcriptionally inhibits homologous recombination repair (HRR) genes

Phase II trial of pembrolizumab in patients with solid tumors functionally competent or deficient for the Fanconi Anemia repair pathway

Investigating the interaction of the ATR inhibitor, AZD6738, with platinum chemotherapy

BRCA reversion mutations in circulating cell-free tumour DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma (HGOC)

Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models

An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models

Evaluation of drugdrug interaction of itraconazole and ivosidenib (AG-120), an oral, potent, targeted, small molecule inhibitor of mutant IDH1, in healthy subjects

DCC-2618, a broad-spectrum inhibitor of KIT and PDGFRA mutants, synergizes with inhibitors of the MAPK pathway

Expedited Development of AVB-S6 through the use of a Proprietary Biomarker in Healthy Volunteers to Guide Dosing in Oncology Studies

Cell cycle intervention beyond palbociclib; preclinical discovery of the CDK2/4/6 inhibitor PF-06873600

Impact of regulatory T cells on cellular cytotoxicity induced by ERY974, a novel T cellredirecting bispecific antibody targeting glypican-3

Phase I dose expansion results from a multicenter, open-label study of the MET inhibitor capmatinib (INC280) in adult patients with MET-dysregulated advanced NSCLC

Phase I dose-finding study of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (pts) with advanced malignancies